Saudi National Pavilion at London Design Biennale 2025: “Good Water” Invites us to Rethink Our Relationship With Water

The exhibition is conceived by the multidisciplinary design collective including Alaa Tarabzouni, Aziz Jamal, Dur Kattan and Fahad bin Naif, whose design approach questions, disrupts, and reimagines systems of access and distribution of water and our relationship with it. The Saudi National Pavilion is defined by a sabeel – a free water fountain and symbol […]

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

(NasdaqGM:MREO), Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE)

Majority of General Counsel Indicate Openness to Using AI in Nearly Every Major Legal Use Case, According to The General Counsel Report

(NYSE:FCN), WASHINGTON, March 26, 2025 (GLOBE NEWSWIRE) — More than two-thirds of general counsel have expressed interest in using generative artificial intelligence within the legal department, according to part two of The General Counsel Report 2025 from FTI Consulting, Inc. (NYSE: FCN) and global legal technology company Relativity. Alongside growing interest in AI within legal,

DeFi Technologies Announces Shareholder Call to Discuss 2024 Financial Results

(the “Company” or “DeFi Technologies”) (CBOE CA: DEFI) (GR: R9B) (OTC: DEFTF), a financial technology company that pioneers the convergence of traditional capital markets with the world of decentralised finance (“DeFi”), today announces it will conduct a shareholder call on Monday March 31, 2025 at 12:00 p.m. EST to discuss its financial performance for the

NetDragon Announces 2024 Annual Financial Results, Fully Embraces the World of Artificial Intelligence

Profit Before Tax Up19% YoY Final Dividend Increased by 25% YoY toHK$0.5 Per Share NetDragon Websoft Holdings Limited (“NetDragon” or the “Company”; Hong Kong Stock Code: 0777), a global leader in building internet communities, announced its financial results for fiscal year 2024 today. NetDragon's management team will be hosting a conference call and webcast on

Half of Canadian small businesses no longer feel the U.S. is a reliable trading partner

Many taking action to reduce their dependence due to tariffs The widespread business disruption caused by U.S.-Canada tariffs is leading Canadian small business owners to shift their suppliers and investments to domestic and international markets other than the U.S., according to new survey data by theCanadian Federation of Independent Business (CFIB). “Businesses need more certainty,

SEALSQ’s QS7001 Secure Chip to Quantum-Proof Blockchain Platforms

(NASDAQ:LAES),(NASDAQ:LAESV), Geneva, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) — The QS7001 Chip in now going through certification process while its release is set for Q4 2025 The QS7001 Chip strengthens blockchain ecosystems against quantum threats with NIST-compliant post quantum cryptographic algorithms SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and

Entourage Health Increases Senior Secured Credit Facility

(TSX-V:ENTG),(Frankfurt:4WE0.F),(OTC US:ETRGF),(Other OTC:ETRGF),(Boerse Frankfurt – Freiverkehr:4WE.F), TORONTO, March 26, 2025 (GLOBE NEWSWIRE) — Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (“Entourage” or the “Company“), a Canadian producer and distributor of award-winning cannabis products, announced today that it has entered into amendments (the “Amendments“) to its subordinated amended and restated credit facility entered into

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

(NasdaqGM:WVE), Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

(NASDAQ:KURA), – Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA),

Scroll to Top